Story perspectives

SpotitEarly's AI-Powered Breath Test Detects Cancer at Home

10/10/2025

Summary

Story summary

SpotitEarly, an Israeli biotech company, is developing an at-home cancer screening test.
The test combines canine olfaction with artificial intelligence to analyze breath samples.
Breath samples are collected at home, analyzed by trained beagles, then confirmed by AI.
A Nature study shows 94% accuracy for early-stage cancers, including breast, colorectal, prostate, and lung.
SpotitEarly plans a U.S. launch at about $250 per test and has raised $20.3 million for trials.

1 of 1

Story summary

SpotitEarly, an Israeli biotech company, is developing an at-home cancer screening test.
The test combines canine olfaction with artificial intelligence to analyze breath samples.
Breath samples are collected at home, analyzed by trained beagles, then confirmed by AI.
A Nature study shows 94% accuracy for early-stage cancers, including breast, colorectal, prostate, and lung.
SpotitEarly plans a U.S. launch at about $250 per test and has raised $20.3 million for trials.